Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
67
resultados
Última actualización
04/07/2025 [06:54:00]
Resultados 50 a 67 de 67
Resumen de: WO2025099460A1
The invention relates to calibration standards for use in a single-molecular detection methods, in particular to quantify protein complexes in a sample.
Resumen de: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Resumen de: WO2025099458A1
The invention relates to methods of determining whether a subject has, or is at risk of developing, a neurodegenerative disorder using ultra-sensitive techniques, in particular a single-molecular array detection method.
Resumen de: KR20250064344A
본 발명은 알츠하이머병 동물 모델에서 안구 내 알츠하이머 치매 병리 물질의 침착을 평가하는 방법에 관한 것으로, 본 발명의 방법에 따르면, 알츠하이머병 동물 모델의 안구 내 병리 물질(β-아밀로이드 플라크)의 발현을 평가할 수 있는 바, 관련 용도로 유용하게 사용될 수 있다.
Resumen de: WO2025093893A1
The present invention relates to methods of measuring the presence and/or levels of a combination of five biomarkers in a sample, said biomarkers being neurofilament light (NfL) polypeptide, glial fibrillary acidic protein (GFAP), β-Amyloid 1-42 (Aβ1-42), β-Amyloid 1-40 (Aβ1-40), and phosphorylated Tau (p-Tau181, pTau-231 and/or p-Tau217). The methods can be used to predict the subject's risk or likelihood of having and/or developing Alzheimer's disease, thus also provided is a method of predicting a subject's risk or likelihood of having and/or developing Alzheimer's disease, said method comprising measuring the presence of and/or the levels of the combination of five biomarkers. Further provided is a method of prognosing or diagnosing Alzheimer's disease in a subject comprising the methods of measuring the presence of and/or the levels of the combination of five biomarkers, and a method of treating Alzheimer's disease comprising predicting a subject's risk or likelihood of developing or having Alzheimer's disease using the methods of measuring the presence and/or levels of the combination of five biomarkers and administering a treatment if the risk or likelihood exceeds a threshold value.
Resumen de: WO2025094139A1
This application is directed to detecting presence or quantity of at least two different molecules. A sensor includes a plurality of chambers, a nanowell array electrode, and a circuit board platform. The sensor separates, cleaves, filters, and detects the at least two different molecules selected from the group consisting of Aβ peptides and tau-protein from a sample in the plurality of nanowells. In some embodiments, the presence or quantity of at least three different Aβ peptides is detected, and an effective amount of a therapeutic compound is administrated to treat Alzheimer in a subject in need thereof.
Resumen de: WO2025096789A1
A method of assaying for activity of a protease enzyme corresponding to a disease in a subject includes selectively capturing an extracellular vesicle (EV) from a sample from the subject; contacting the EV after the capturing with a probe molecule, the probe molecule including a peptide, a fluorescent moiety on a first end of the peptide and a quenching moiety on a second end of the peptide to provide a Fluorescence Resonance Energy Transfer (FRET) pair separated by the peptide, the peptide containing a cleavage sequence for the protease enzyme; and measuring a fluorescence of at least the fluorescent moiety after the contacting to indicate a presence or absence of the occurrence of cleavage of the peptide by the protease enzyme.
Resumen de: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Resumen de: WO2025095508A1
The present invention relates to a biohybrid robot including an eye/brain organoid, a motor nerve spheroid, and a muscle bundle, and a manufacturing method therefor. The universal biohybrid robot according to the present invention can generate movement of muscle cells by an electrophysiological signal generated in the eye/brain organoid like a human motor system by using light stimulation and a neurotransmitter. It is expected that the present invention can be used in a disease model simulating a signal transmission system of the human body by combining various neurodegenerative diseases, such as Parkinson and Alzheimer's disease models, and eye tumor models in the future, and can be used to manufacture a drug screening platform that leverages the movement of biohybrid robots composed of living tissues.
Resumen de: US2025145722A1
Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Resumen de: US2025147041A1
Methods for the detection or quantitation of amyloid beta include detecting amyloid beta or fragments thereof by mass spectrometry. The methods may also include determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). Such methods may include the diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: US2025147049A1
The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.
Resumen de: EP4549585A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Resumen de: EP4548992A2
Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: KR20250060844A
본 발명은 퇴행성 뇌질환의 진단을 위한 바이오 마커 조성물에 관한 것으로, 퇴행성 뇌질환의 진단을 위한 바이오 마커 조성물에 관한 것으로, 구체적으로 정상인, 경도인지장애(MCI) 환자, 및 알츠하이머(AD) 환자를 구분하기 위해, 혈액 내 바이오마커로 Aβ40(아밀로이드 베타 40), Aβ42(아밀로이드 베타 42), BDNF(뇌유래신경성장인자), Tau(타우), NSE(neuron-specific enolase), GFAP(Glial fibrillary acidic protein), UCH-L1(Ubiquitin carboxy-terminal hydrolase L1), PIN1(peptidyl-prolyl isomerase), CRMP2(collapsing response mediator protein-2), 인산화-타우231(Phospho-Tau231), 및 OMP(olfactory marker protein)의 수준을 측정하고, 이들의 유연관계를 파악함으로써, 정상인, 경도인지장애(MCI) 환자, 및 알츠하이머(AD) 환자를 구분하는 바이오마커 조성물을 제공하는 것이다.
Resumen de: KR20250060843A
본 발명은 퇴행성 뇌질환의 진단을 위한 바이오 마커 조성물에 관한 것으로, 퇴행성 뇌질환의 진단을 위한 바이오 마커 조성물에 관한 것으로, 구체적으로 정상인, 경도인지장애(MCI) 환자, 및 알츠하이머(AD) 환자를 구분하기 위해, 혈액 내 바이오마커로 Aβ40(아밀로이드 베타 40), Aβ42(아밀로이드 베타 42), BDNF(뇌유래신경성장인자), Tau(타우), NSE(neuron-specific enolase), GFAP(Glial fibrillary acidic protein), UCH-L1(Ubiquitin carboxy-terminal hydrolase L1), PIN1(peptidyl-prolyl isomerase), CRMP2(collapsing response mediator protein-2), 인산화-타우231(Phospho-Tau231), 및 OMP(olfactory marker protein)의 수준을 측정하고, 이들의 유연관계를 파악함으로써, 정상인, 경도인지장애(MCI) 환자, 및 알츠하이머(AD) 환자를 구분하는 바이오마커 조성물을 제공하는 것이다.
Nº publicación: KR20250060358A 07/05/2025
Solicitante:
JHK MEDICAL SCIENCE INC [KR]
(\uC8FC)\uC81C\uC774\uC5D0\uC774\uCE58\uCF00\uC774 \uBA54\uB514\uCEEC \uC0AC\uC774\uC5B8\uC2A4
Resumen de: KR20250060358A
본 발명은 퇴행성 뇌질환의 진단을 위한 바이오 마커 조성물에 관한 것으로, 퇴행성 뇌질환의 진단을 위한 바이오 마커 조성물에 관한 것으로, 구체적으로 정상인, 경도인지장애(MCI) 환자, 및 알츠하이머(AD) 환자를 구분하기 위해, 혈액 내 바이오마커로 Aβ40(아밀로이드 베타 40), Aβ42(아밀로이드 베타 42), BDNF(뇌유래신경성장인자), Tau(타우), NSE(neuron-specific enolase), GFAP(Glial fibrillary acidic protein), UCH-L1(Ubiquitin carboxy-terminal hydrolase L1), PIN1(peptidyl-prolyl isomerase), CRMP2(collapsing response mediator protein-2), 인산화-타우231(Phospho-Tau231), 및 OMP(olfactory marker protein)의 수준을 측정하고, 이들의 유연관계를 파악함으로써, 정상인, 경도인지장애(MCI) 환자, 및 알츠하이머(AD) 환자를 구분하는 바이오마커 조성물을 제공하는 것이다.
BOPI
Sede Electrónica
